MiNK Therapeutics

Company snapshot

XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal a

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MiNK Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for MiNK Therapeutics.

1. Jun 5, 2026 Clinical update

   agenT-797 — Phase 1

2. May 23, 2026 Clinical update

   agenT-797 — Phase 1

3. May 23, 2026 Clinical update

   agenT-797 — Phase 1

4. Sep 23, 2025 Patent grant

   Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus

5. Aug 19, 2025 Patent grant

   T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof

View all clinical trial activity →

• What is MiNK Therapeutics?

  XNK Therapeutics is a biotech organization headquartered in NEW YORK, NY, SE. It trades on NYSE under ticker INKT. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Respiratory Distress Syndrome, Adult, Tumor, Solid. NovaPharmaNews links 3 clinical pro

• Is MiNK Therapeutics publicly traded?

  Yes. MiNK Therapeutics is listed with ticker INKT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does MiNK Therapeutics develop or market?

  We link 1 drug profile(s) where MiNK Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mink-therapeutics#company-drugs.

• What are the latest developments for MiNK Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does MiNK Therapeutics focus on?

  MiNK Therapeutics focuses on Relapsed/Refractory Multiple Myeloma, Respiratory Distress Syndrome, Adult, Tumor, Solid based on our analysis of their pipeline programs and drug development activities.